TIAA CREF Investment Management LLC lowered its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 3.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 75,274 shares of the biopharmaceutical company’s stock after selling 2,413 shares during the period. TIAA CREF Investment Management LLC’s holdings in Revance Therapeutics were worth $1,566,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Revance Therapeutics during the fourth quarter worth approximately $174,000. American International Group Inc. boosted its stake in Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 834 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Revance Therapeutics by 5.9% in the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 1,524 shares during the last quarter. Swiss National Bank boosted its stake in Revance Therapeutics by 6.8% in the first quarter. Swiss National Bank now owns 32,850 shares of the biopharmaceutical company’s stock worth $683,000 after buying an additional 2,100 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Revance Therapeutics by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 33,722 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 1,650 shares during the last quarter. Hedge funds and other institutional investors own 87.29% of the company’s stock.

Shares of Revance Therapeutics, Inc. (NASDAQ RVNC) traded up 1.99% on Friday, reaching $23.05. 9,178 shares of the company were exchanged. The firm’s 50 day moving average price is $24.47 and its 200 day moving average price is $21.89. The stock’s market capitalization is $710.38 million. Revance Therapeutics, Inc. has a 52 week low of $12.35 and a 52 week high of $28.30.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.03. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. Revance Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. Equities research analysts anticipate that Revance Therapeutics, Inc. will post ($3.75) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/revance-therapeutics-inc-rvnc-position-lowered-by-tiaa-cref-investment-management-llc.html.

A number of research firms have recently commented on RVNC. BidaskClub cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday. Piper Jaffray Companies set a $28.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. ValuEngine upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, Aegis restated a “buy” rating and set a $36.00 price objective on shares of Revance Therapeutics in a research report on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $34.75.

In other news, CFO Lauren P. Silvernail sold 1,793 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $20.20, for a total value of $36,218.60. Following the sale, the chief financial officer now directly owns 36,566 shares of the company’s stock, valued at approximately $738,633.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO L Daniel Browne sold 19,713 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $20.35, for a total transaction of $401,159.55. Following the completion of the sale, the chief executive officer now directly owns 183,932 shares in the company, valued at $3,743,016.20. The disclosure for this sale can be found here. Insiders sold a total of 33,793 shares of company stock worth $685,576 over the last ninety days. Insiders own 18.86% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.